Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
DUBLIN - On Tuesday, Alkermes plc (NASDAQ:ALKS) reported second-quarter financial results that exceeded analyst expectations, delivering strong performance across its proprietary product portfolio.
The biopharmaceutical company’s shares were up 5.16% in pre-market trading after the announcement.
The company posted adjusted earnings of $0.52 per share for the quarter, significantly beating the analyst estimate of $0.36. Revenue came in at $390.7 million, well above the consensus expectation of $347.16 million, despite being down 2.1% compared to $399.1 million in the same quarter last year.
Alkermes saw growth across all three of its proprietary products, with total proprietary net sales reaching $307.2 million, up 14% YoY. LYBALVI revenues grew 18% to $84.3 million, ARISTADA revenues increased 18% to $101.3 million, and VIVITROL revenues rose 9% to $121.7 million compared to the second quarter of 2024.
"Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes.
The company maintained a strong financial position with $1.05 billion in cash, cash equivalents and investments as of June 30, 2025, up from $916.2 million at the end of the previous quarter.
Alkermes reiterated its financial expectations for 2025, which were initially set in February. The company also highlighted recent positive topline results from its Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1, with detailed results to be presented at the upcoming World Sleep Congress.
The positive quarterly performance reinforces Alkermes’ position in the neuroscience space as it continues to advance its pipeline while generating strong revenue from its commercial portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.